These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 19429509)
21. [Biosimilar: can we manage biopharmaceutical heterogeneity?]. Ranieri E G Ital Nefrol; 2008; 25(3):275. PubMed ID: 18473296 [No Abstract] [Full Text] [Related]
22. European regulatory guidelines for biosimilars. Wiecek A; Mikhail A Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790 [TBL] [Abstract][Full Text] [Related]
23. [The problematic of original and generic drugs and biosimilars--switching of drugs today and tomorrow with the main targeting on biotechnologies-associated risks]. Svoboda T Klin Onkol; 2010; 23(6):416-20. PubMed ID: 21351418 [TBL] [Abstract][Full Text] [Related]
24. [Similarity of biotechnology-derived drugs: regulatory framework and specificity]. Prugnaud JL Ann Pharm Fr; 2008 Aug; 66(4):206-11. PubMed ID: 18847566 [TBL] [Abstract][Full Text] [Related]
25. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. Strober BE; Armour K; Romiti R; Smith C; Tebbey PW; Menter A; Leonardi C J Am Acad Dermatol; 2012 Feb; 66(2):317-22. PubMed ID: 22243723 [TBL] [Abstract][Full Text] [Related]
26. Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals. Blackstone EA; Fuhr JP Future Med Chem; 2010 Nov; 2(11):1641-9. PubMed ID: 21428836 [TBL] [Abstract][Full Text] [Related]
28. Development of biosimilars--pharmacokinetic and pharmacodynamic considerations. Wang YM; Chow AT J Biopharm Stat; 2010 Jan; 20(1):46-61. PubMed ID: 20077248 [TBL] [Abstract][Full Text] [Related]
29. Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products. Halim LA; Brinks V; Jiskoot W; Romeijn S; Haselberg R; Burns C; Wadhwa M; Schellekens H J Pharm Sci; 2016 Feb; 105(2):542-550. PubMed ID: 26869417 [TBL] [Abstract][Full Text] [Related]
30. Current regulatory and scientific considerations for approving biosimilars in Iran. Hadavand N; Valadkhani M; Zarbakhsh A Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077 [TBL] [Abstract][Full Text] [Related]
32. The protein science of biosimilars. Kuhlmann M; Covic A Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v4-8. PubMed ID: 16959791 [TBL] [Abstract][Full Text] [Related]
33. [Biosimilar products comparable to original preparations. The Medical Products Agency will not yet classify the agents as generics]. Welin M; Liliemark J Lakartidningen; 2009 Jun 3-9; 106(23):1547-8. PubMed ID: 19583011 [No Abstract] [Full Text] [Related]